Affordable Growth. Analyze the stocks which are showing good growth, decent profitability and health and are not overvalued from a fundamental perspective.
NVO gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making NVO a very profitable company, without any liquidiy or solvency issues. An interesting combination arises when we look at growth and value: NVO is growing strongly while it also seems undervalued. This makes NVO very considerable for value and growth and quality investing!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 21.68% | ||
ROE | 70.38% | ||
ROIC | 43.02% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 46.16% | ||
PM (TTM) | 34.78% | ||
GM | 84.67% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.62 | ||
Debt/FCF | 1.48 | ||
Altman-Z | 5.62 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.74 | ||
Quick Ratio | 0.55 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 20.07 | ||
Fwd PE | 16.76 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 29.02 | ||
EV/EBITDA | 13.63 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.57% |